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A running title: Mab to VLA-4 protects skin flap against 1/R injury 
Abstract: In recent years, various adhesion molecules have been discovered. 
Very late antigen-4 (VLA-4) as one of the integrin family is an adhesion 
molecule playing an important role in migrating and infiltrating lymphocytes to 
the site of inflammation. In the present study, we investigated whether the 
administration of antiVLA-4 antibody reduces the inflammation in 25 male 
Sprague-Dawley rat model (225-250g) of ischemia reperfusion injury skin flap. 
A superficial epigastric arteriovenous pedicle flap with a size of 45×30mm was 
introduced on the right inguinal area and the clamp was removed after 9 hours 
for ischemia. Fifteen minutes prior to the clamp release, the rats were divided 
into an anti-VLA-4 administered (0.20mg/kg) treatment group (n=lO), a 
saline-treated control group (n= 10) or a sham group that has been clamped for 5 
minutes under the same condition (n=S). The rats were followed up for seven 
days. The area of survived skin flap in the treatment group (78.0%) was 
significantly improved compared to that of the control group (18.3%). As for the 
histological findings inflammatory findings, such as severe inflammatory cell 
infiltration and edema were observed in the control group, but those of the 
treatment group were mild and showed a tissue structure similar to that of the 
sham group. Based on these results, ithas been suggested that anti-VLA-4 
monoclonal antibody can be used as an anti-inflammation agent. However, 
further studies are necessary to elucidate its detailed mechanism. 
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Introduction 
In recent years, various adhesion molecules have been discovered. A series of 
these molecules called cell adhesion molecules are involved in cellular 
interaction and play important roles in inflammation and the regulation of 
immunoreaction 1). They play an important role on the progress of 
inflammation by activated leucocytes adhering on vascular endothelial cels. The 
tissue infiltration process in inflammation reaction can be classified into the 
following three steps: rolling step, strong adhesion step, and transmigration step. 
In each step, di百erentadhesion molecules are involved. 
The phenomenon called ischemia reperfusion injury is known to play 
important roles in the mechanism of skin flap survival and necrosis. Especially, 
it has been suggested that the changes against vascular endothelial cells in 
ischemia reperfusion injury are involved in preventing the skin flap survival to 
cause necrosis2-6). To elucidate the mechanisms of skin flap survival and 
necrosis, a rat model of ischemia reperfusion injury skin flap has been 
developed. Therefore, we believe it is useful to utilize this rat model of 
ischemia reperfusion injury skin flap to understand the causative agents 
responsible for inflammation6'7). Integrin as one of the adhesion molecules is 
known to be highly involved in regulation of intercellular or extracellular matrix 
adhesion or intracellular signal transduction via adhesion8). 
Very late antigen-4 (VLA-4 hereina立er),which belongs to the integrin family, 
is considered to be involved with the migration of lymphocytes to the site of 
inflammation9). Thus, we carried out the experiment to investigate whether the 
administration of anti-VLA-4 antibody against VLA-4 reduces the inflammation 
reaction or not and, if it does, how much itdoes using the ischemia reperfusion 
injury skin flap model, and we report the results along with literature review. 
Materials and Methods 
Ische，ηiα－reperfusion injury skin flαp model 
Twenty-five male Sprague-Dawley rats (8-10 weeks of age, 225-250 grams, 
Saitama Experimental Animals Supply Co., Ltd., Saitama, Japan) were used in 
the experiment. The animals were housed in wire-mesh cages and given企ee
access to pellet diet (Nosan Corporation, Kanagawa, Japan) and drinking water 
(tap water). 
Ketamine hydrochloride (25 mg/kg) was administered intraperitoneally as 
anesthesia. After pain elimination the abdomen was shaved and 45×35 mm 
pedicled skin flaps with superficial epigastric veins and arteries as pedicles were 
designed in the right inguinal region and elevated. Then the skin flap pedicles 
were clamped (Fig. 1) 6). The animal experiment was conducted ethically based 
on the Showa University animal experiment guidelines. 
lschemic interναf 
The ischemic interval was 9 hours, or 5 minutes for the sham group. 
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Antibody αdminis tration 
The anti-very late antigen-4 (VLA-4) antibody (0.20 mg/kg) (monoclonal 
anti-rat VLA-4: CD49d) (TA-2, Cape Cod Incorporation, Falmouth, MA, USA) 
against very late antigen-4 (VLA-4) was administered by intravenous injection 
to the caudal vein 15 minutes before releasing the clamp. Sterilized saline at 
the same dose was administered in the same manner as a control. 
Experimental groups 
An anti VLA-4 antibody treatment group (n=lO) and a physiological saline 
control (n=lO) were observed over 7 days. A skin flap was elevated in the 
same manner in a sham group (n=5), but the clamp was released a食er5 minutes. 
The animals were euthanized at the end of the 7-day observation by an overdose 
of anesthesia, and histological examination of the skin flaps was conducted (Fig 
2). 
Method of evaluαtion 
Skin flaps were evaluated by macroscopic observation and histological 
analysis. 
1) Skin flap survival area ratio 
The area ratio of the skin flap survival regions and necrotic regions was 
calculated by trace based on the template method of Morris et al., and the 
survival area ratio was obtained Io)_ 
5 
2) Histological examination 
Samples were prepared by hematoxylin-eosin staining. Tissue samples were 
then observed for inflammation findings and their extent, and for the condition 
within blood vessels. 
Stαtis ticαl anαlysis 
The data were expressed as mean土SD.Mann-Whitney statistical analysis 
was applied to evaluate survival difference between control and treatment 
groups. Differences of p< 0.05 were considered to be statistically significant. 
Results 
Skin flap surνiναlαrearαtio 
Noncomparative analysis of the treatment group administered anti-VLA-4 
antibody and the control group administered physiological saline was conducted. 
Comparison of macroscopic findings showed that skin flap survival in the 
treatment group was good, and that skin flap morphology and color were close 
to the sham group. In the control group, however, skin flaps showed severe 
inflammation accompanied by partial necrosis (Fig. 3). 
In comparison of the mean skin flap survival area ratio in each group on day 7 
after reperfusion, improved skin flap survival ration was observed with 
statistically significant difference (p<0.005) at 78.0土39.8%in the 9-hour 
ischemia antibody administration group compared to 18.3士19.6%in the control 
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group (Fig. 4). 
Histological exαmination 
In the treatment group, although inflammation findings were observed and 
disorganized structure was partially observed on the skin surface, the levels of 
inflammation cell infiltration and edema were relatively mild, vascular lumep 
was preserved, with tissue structure similar to those of the sham group. In 
contrast, in the control group, inflammation cell infiltration, edema and necrosis 
were observed. In addition, vascular lumen was filled with erythrocytes, 
indicating the formation of blood clots, which was dramatically different from 
the condition of vascular lumen of the treatment group (Fig. 5). 
Discussion 
Very late antigen-4 (VLA-4) is one of the beta 1 integrin families and also 
known as alpha 4 beta 1 integrin, CD49d/CD29, or lymphocyte Peyer’s patch 
HEV adhesion molecule 2(LP.Al¥ι2). It consists of a heterodimer of a l 50kD 
(on SDS-PAGE under reduced condition) alpha 4 chain subunit and a 130kD of 
beta 1 chain subunit11). Both alpha 4 chain and beta 1 chain are type I 
membrane proteins spanning cell membrane once and having their N-te1minus 
on the exterior side of the cell and the C-tenninus on the cytoplasmic side of the 
cel. The alpha 4 chain (999 amino acids) is consisted of an extracellular 
domain (944 amino. acids) with seven tandem repeats domain, a trans membrane 
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domain (23 amino acids), and a short intracellular domain (32 amino acids) 
(Fig.6). 
VLA-4 is expressed in T-cells, B-cells, hematocytes such as monocytes, NK 
cells, eosinophils, neutrophils, basophils, thymocytes, myelomonocytes, 
erythroid progenitors, lymphoid progenitors, along with melanomas and muscle 
cels. 
Activated VLA-4 (CD49d/CD29) attached on the vascular endothelial cells 
are fibronectin receptors. Unlike typical fibronectin receptor VLA-5, the binding 
of VLA-4 with fibronectin is not via RGD sequence12・13). VLA-4 induces 
migration of lymphocytes and monocytes to the site of inflammation by binding 
with VCAM-1 ( vascular cel adhesion molecule-I) on vascular endothelial cells 
induced during inflammation14>. Then, the binding of VLA-4 with VCMιI 
leads to both rolling and adhesion of leucocytes (10Alonl95) (Fig. 7). In short, 
it is believed that activated lymphocytes and macrophages expressing VLA-4 
partially facilitate extravascular migration by adhering through VCAM-1 which 
is over-expressed on the vascular endothelial cell by inflammatory cytokines15). 
In addition to TCR (T cell receptor)/CD3 complex which plays a major role in 
antigen-specific activation of T cells, VLA-4 is involved with sub-signal 
transduction along with CD28. 
As a VLA-4 ligand, fibronectin, VCAM-1 (vascular cell adhesion molecule-I), 
and invasin are reported12). As to fibronectin, VLA-4 recognizes an EILDV 
sequence -of CS-1 site by alternative splicing to bind with CS-5 site or Hep 11 
12 16 17) site 1 It is also involved with cell-cell adhesion by binding with VCAl¥ιl 
expressed on vascular endothelial cells and myeloid stromal cells 18). 
Furthermore, itis also involved with bacterial invasion by binding with invasin 
on the surface of certain bacteria. 
In ischemia reperfusion injury, which is a type of inflammation reaction, 
various adhesion molecules expressed on activated leucocytes and vascular 
endothelial cells are involved. To elucidate this mechanism, an experimental 
model of ischemia reperfusion in ury skin flap is developed 19). It has been 
reported that, in this ischemia reperfusion skin flap model, inflammation was 
significantly suppressed by the administration of anti-ICAM」 monoclonal
antibody6). 
In the present study, a significant suppressive effect of inflammation was 
observed by the administration of anti-VLA-4 monoclonal antibody. VLA-4 is 
considered to be involved with the rolling, adhesion and extravascular migration 
of leucocytes via VCAM-1 over-expressed on vascular endothelial cells by 
inflammatory cytokines. Therefore, itsuggested that the administration of 
anti-VLA-4 antibody blocks the adhesion between activated VCAM-1 on 
vascular endothelial cells and leucocytes during inflammation, consequently the 
rolling is also blocked to result in suppression of the inflammation. 
Ken-an etαJ suggested that in ischemia reper負1sioninjury, platelet activating 
factor (PAF), IL-6, and tumor necrosis factor (TNF) are induced a丘町
reperfusion to promote tissue damage20). Relating to this, there are several 
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studies reporting. that the administrations of PAP-antagonist or tacrolimus 
significantly reduced ischemia reperfusion inj町y7). For its action mechanism, 
inhibition ・of neutrophil-induced superoxide radical formation, inhibition of 
neutrophil-induced mediators such as TNF or LTB4, suppression of TNF or IL-6 
induction by reperfusion, and attenuation of neutrophil-vascular endothelial cell 
binding interaction by suppression of CD 1/CD 18 activities are mentioned. 
Experimentally, it has been revealed that VLA-4 is related to the development 
of multiple sclerosis based on the experimental mouse model of autoimmune 
encephalomyelitis. In addition,. VLA-4 is also pathologically involved with th・e 
rejection reactions of mouse heart transplant. Furthermore, VLA-4 1s 
pathologic平lyinvolved with bronchial asthma in experimental models of 
ma1mots and rats. In contrast, ithas been suggested that VLA-4 plays a role in 
cellular differentiation in bone ma町owand furthetmore it plays an important 
role in infiltration and metastasis of kidney cancer and acute myeloid 
le叫臼mia21,2).
・ In recent years, clinical application of biological agents, such as 
anti-monoclonal antibody targeting cell surface factors and cytokines have been 
developed, making significant impacts: In short, by adhering with VCAM-1 on 
vascular endothelial cells, VLA-4 is involved with the inflammation-related 
infiltration of lymphocytes and monocytes, and therefore the clinical application 
of the drug inhibiting the VLA-4 adhesion has been projected for the treatment 
of inflammatory diseases and immuno-related pathological conditions23). 
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For the effect on humans, there is a report of a clinical study demonstrating 
the suppression of inflammation by the administration of anti-VLA・4human 
monoclonal antibody (Natalizumab) 24)_ For the patients with multiple sclerosis, 
the administration of Natalizumab significantly decreased the number of 
inflammation foci on MRI in the phase I clinical study. In phase II clinical 
study, its recurrence rate was decreased in the N atalizumab administered 
group25). In addition, ithl:ls been recognized that the repeated administration of 
Natalizumab for over 12 weeks is effective for the treatment of Crohn’s disease 
compared to the placebo administered group in a large-scale clinical triai26). 
However, when Natalizumab was administered to the cases of multiple sclerosis 
and Crohn's disease, the complication of progressive multifocal 
leukoencephalopathy (PML) was reported27-3o)_ Later, itturned out that the 
cause of the complication of PML had been caused by JC virus infection. 
・ This ‘case illustrates the fact that we need to take side effects into 
consideration upon developing and clinically applying various biological agents 
in the future. 
In the present study, we aimed .to reduce inflammation by administering 
anti-VLA-4 monoclonal antibody in rat ischemia reperfusion injury inguinal 
skin flap model. Compared to the saline-treated cont1叫 group,the anti司VLA-4
monoclonal antibody administered group showed significant improvement in 
skin flap survival and significant improvement in histologicai inflammatory 
fi口dings. Based on these results, ithas been suggested that anti-VLA-4 
1 
, 
monoclonal antibody can be used as an anti-inflammation agent. However, 
向rtherstudies are necessary to elucidate its detailed mechanism. 
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Legend 
Fig. 1. 
(A) Diagram for the skin flap model (45x35mm) showing the primary vessels 
and the points where they were occiuded (Tosa Y, et al. 1998). 
(B) Rat inguinal skin flap is elevated. 
Fig. 2. Protocol for anti-VLA-4 antibody administration to ischemia reperfusion 
ip.jury skin flap. 
Fig. 3.Viability of the skin ・flaps in each group. 
(A) Representative .picture of the sham group on Day 7. The skin flap was 
survived at 100%. 
(B) Representative picture of the anti-VLA-4 antibody administered group on 
Day 7. The skin flap was survived at 100%. Some skin flap showed 
approximately 20% necrosis observed in peripherals, but on average, the 
survival rate was approximately 78%. 
(C) Representative picture of the saline-treated control group on Day 7. Entire 
skin flap showed necrosis. On average, the survival rate was 18%. 
Fig. 4. Percentage survival area of the skin flaps in each group. 
Animals in the sham-operated group were ischemic for 5 minutes. 
The viable area treated with monoclonal antibody to VLA-4 was significantly 
higher than the viable area of the flap in the control group. 
Fig. 5. Histological sections from representative flaps. 
Hematoxylin-eosin stain (XI 00) 
(A) Section企omthe sham-operated group showing normal tissue structure a丘町
only 5 minutes of ischemia. 
(B) Slight edema is noted in the papillary dermis with moderate inflammatory 
infiltrate in flaps treated with monoclonal antibody to VLA-4 after 9 hours of 
ischemia. 
(C) I~ control flaps receiving saline vehicle, epidermis was necrotic and the 
dermis showed edema with significant inflammatory infiltration composed of 
lymphocytes. 
Fig. 6. Diagram for VLA・4. VLA-4 is a heterodimer of an alpha 4 chain and a 
betal chain and both chains are type I membrane proteins spanning cell 
membrane once and having their N-terminus on the exterior side of the cell and 
the C-terminus on the cytoplasmic side of the cel. 
Fig. 7. Diagram for vascular lumen. VLA-4 induces migration of lymphocytes 
and monocytes to the site of inflammation by 'binding with 
inflammation-induced VCAM-1 on vascular endothelial cels. 
2 
Fig. 8. Diagram for vascular lumen. The administration of anti-VLA-4 
antibody reduces ~nflammation reaction by inhibiting the binding with VCAM-1 
on vascular endothelial cels. 
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